• Bleeding disorders

Vonvendi Generic Name & Formulations

General Description

Von Willebrand Factor (recombinant); 650 IU VWF:RCo, 1300 IU VWF:RCo; per vial; lyophilized pwd for IV inj after reconstitution; preservative-free; contains polysorbate 80.

Pharmacological Class

Clotting factor.

How Supplied

Single-use vials—1 (w. diluent, supplies)

Generic Availability


Vonvendi Indications


In adults with von Willebrand disease (VWD) for: on-demand treatment and control of bleeding episodes; perioperative management of bleeding; routine prophylaxis to reduce the frequency of bleeding episodes in patients with severe Type 3 VWD receiving on-demand therapy.

Vonvendi Dosage and Administration


Max infusion rate: 4mL/min. ≥18yrs: Bleeding: give recombinant factor VIII (FVIII) with first infusion if baseline plasma FVIII level <40% or is unknown (see full labeling). Individualize; monitor and adjust according to extent and location of bleed. Minor: initially 40–50 IU/kg, then every 8–24hrs as needed. Major: initially 50–80 IU/kg, then 40–60 IU/kg every 8–24hrs for 2–3 days as needed. Perioperative management: see full labeling. Routine prophylaxis: initially 40–60 IU/kg twice weekly; adjust dose up to 60 IU/kg twice weekly if breakthrough bleeding occurs in joints or if severe bleeding occurs.


<18yrs: not established.

Vonvendi Contraindications


Hypersensitivity to hamster or mouse proteins.

Vonvendi Boxed Warnings

Not Applicable

Vonvendi Warnings/Precautions


Risk of thromboembolic events in patients with known risk factors or an excessive rise in FVIII levels; monitor, give prophylaxis if clinically indicated. Discontinue immediately if severe allergic reactions occur. Monitor plasma VWF:RCo, FVIII, and inhibitors to VWF and/or FVIII (if suspected). Pregnancy. Nursing mothers.

Vonvendi Pharmacokinetics

See Literature

Vonvendi Interactions

Not Applicable

Vonvendi Adverse Reactions

Adverse Reactions

Headache, vomiting, nausea, dizziness, arthralgia, joint injury, vertigo, increased ALT, generalized pruritus; thromboembolic events, antibody formation (consider alternatives).

Vonvendi Clinical Trials

See Literature

Vonvendi Note

Not Applicable

Vonvendi Patient Counseling

See Literature